financetom
Business
financetom
/
Business
/
Large-Cap Banks Poised for 'Robust' Q4 Capital Markets Revenue, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Large-Cap Banks Poised for 'Robust' Q4 Capital Markets Revenue, Morgan Stanley Says
Jan 7, 2025 9:11 AM

11:56 AM EST, 01/07/2025 (MT Newswires) -- Major US banks are expected to report "robust" Q4 capital markets revenue, especially in trading and equity capital markets, with Citigroup ( C ) seen as the top pick, Morgan Stanley said Tuesday.

The firm said that JPMorgan Chase ( JPM ) , State Street (STT) and U.S. Bancorp ( USB ) are also among its most preferred stocks heading into the earnings reports.

"While banks already surprised to the upside with strong 4Q24 trading guidance at an early December industry conference, we expect trading revenues could come in even higher given the typical seasonal December slowdown just didn't happen," Morgan Stanley said in a note to clients. "We expect capital markets beats in the quarter, positive commentary on 2025 pipelines, the benefit of a steeper curve to drive up 2025 guidance with our 2025 EPS median 4% above the Street."

The brokerage expects Citigroup's ( C ) Q4 earnings of $1.24 per share, which it said was 3% above Wall Street's estimates, while its investment banking revenue is expected to grow 37% year-over-year. Morgan Stanley projects the company's 2025 revenue at $84.1 billion, compared with the Street's $83.1 billion view.

The firm pegs JPMorgan's ( JPM ) Q4 EPS at $4.43, which is said was 11% above the Street's estimates.

For State Street, Morgan Stanley expects both an earnings beat and upbeat outlook, along with potential clarity on its chief financial officer transition, according to the note.

"USB comes into the quarter with a nice set-up to deliver an EPS beat together with upbeat guidance for the full year," Morgan Stanley said.

Price: 74.04, Change: +1.30, Percent Change: +1.79

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved